Clopidogrel contraindications: Difference between revisions

Revision as of 16:25, 6 March 2014

Clopidogrel
PLAVIX^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Clopidogrel
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]

Adapted from the FDA Package Insert.

@@ Line 1: / Line 1: @@
-* [[Hypersensitivity]] to the drug substance or any component of the product.
+__NOTOC__
-* Active pathological bleeding such as [[peptic ulcer]] or [[intracranial hemorrhage]].
+{{Clopidogrel}}
+{{CMG}}; {{AE}} {{JH}}
+==Title==
-{{FDA}}
+<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PLAVIX (CLOPIDOGREL BISULFATE) TABLET, FILM COATED [BRISTOL-MYERS SQUIBB/SANOFI PHARMACEUTICALS PARTNERSHIP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01b14603-8f29-4fa3-8d7e-9d523f802e0b | publisher =  | date =  | accessdate = }}</ref>
+==References==
+{{Reflist}}
+{{FDA}}
+[[Category:Cardiovascular Drugs]]
 [[Category:Drugs]]